Osteopontin can act as an effector for a germline mutation of BRCA1 in malignant transformation of breast cancer-related cells.
Breast cancer-associated 1 (BRCA1) plays an important role in breast cancer initiation and progression through its functions in the cell cycle and DNA repair processes; however, its role in metastatic development in human breast cancer is still poorly understood. We have previously shown that osteopontin (OPN) expression was suppressed by wild-type BRCA1 (Wt.BRCA1) and that a natural mutant allele of BRCA1 (Mut.BRCA1) diminished the effect of Wt.BRCA1 on OPN in vitro. In this study, we show that while Wt.BRCA1 suppresses OPN-induced metastasis in a rat syngeneic system, Mut.BRCA1 enhances the development of metastasis through OPN, suggesting that OPN and BRCA1 work closely to regulate metastatic development in the rat. To test whether these findings are relevant to human breast cancer, we have investigated the relationship between BRCA1, OPN, and metastatic properties in human breast cancer-related cells. Using western blot analysis, we show that Wt.BRCA1 suppresses, while Mut.BRCA1 enhances, OPN protein expression; and in parallel that Wt.BRCA1 suppresses, while Mut.BRCA1 enhances, OPN-mediated in vitro properties associated with the metastatic state in both MCF-7 and MDA MB435s cells. Overall, these results suggest that Mut.BRCA1 can elicit some of the changes involved in metastatic progression in human breast cancer via the overexpression of OPN.
El-Tanani
Mohamed K
MK
Centre of Cancer Research and Cell Biology, Queen's University Belfast, Belfast, Ireland. m.el-tanani@qub.ac.uk
Yuen
Hiu-Fung
HF
Shi
Zhanzhong
Z
Platt-Higgins
Angela
A
Buckley
Niamh E
NE
Mullan
Paul B
PB
Harkin
Denis Paul
DP
Johnston
Patrick G
PG
Rudland
Philip S
PS
D000818:Animals; D001943:Breast Neoplasms / Q000235:genetics / Q000473:pathology*; D002448:Cell Adhesion; D045744:Cell Line, Tumor; D049109:Cell Proliferation; D002471:Cell Transformation, Neoplastic; D005260:Female; D019398:Genes, BRCA1; D018095:Germ-Line Mutation; D006801:Humans; D009361:Neoplasm Invasiveness; D053495:Osteopontin / Q000235:genetics / Q000502:physiology*; D051381:Rats; D017208:Rats, Wistar; D014162:Transfection
D053495:Osteopontin
J Biol Chem. 2001 Nov 9;276(45):41675-82
11522780
J Natl Cancer Inst. 1983 Dec;71(6):1227-40
6418941
Clin Exp Metastasis. 1998 Feb;16(2):129-39
9514094
Cancer Res. 2002 Jun 15;62(12):3417-27
12067984
Surgery. 2008 Jun;143(6):803-12
18549897
Front Biosci. 2008 May 01;13:4276-84
18508510
Exp Cell Res. 2009 Jan 15;315(2):304-12
19026636
Mol Cell. 1999 Oct;4(4):511-8
10549283
Invasion Metastasis. 1991;11(4):204-15
1765433
Breast Cancer Res Treat. 2007 Jul;104(1):13-9
17004106
Oncogene. 2008 Dec 4;27(57):7139-49
18794800
J Biol Chem. 2006 Sep 8;281(36):26587-601
16807234
J Natl Cancer Inst. 1999 Jun 2;91(11):943-9
10359546
Oncogene. 1996 Jul 4;13(1):97-104
8700559
Science. 2003 Oct 24;302(5645):591-3
14576418
Am J Pathol. 2006 Jul;169(1):233-46
16816376
Clin Cancer Res. 1997 Apr;3(4):605-11
9815727
Oncogene. 1999 Jul 22;18(29):4237-46
10435636
Clin Cancer Res. 2006 Jun 1;12(11 Pt 1):3337-43
16740755
Proc Natl Acad Sci U S A. 2000 May 9;97(10):5208-13
10792030
Clin Exp Metastasis. 2004;21(6):543-52
15679052
J Biol Chem. 2004 May 14;279(20):20794-806
14990565
FASEB J. 1993 Dec;7(15):1475-82
8262332
J Biol Chem. 1999 Jun 25;274(26):18808-12
10373498
Lancet. 1996 May 25;347(9013):1493
8676668
Science. 1994 Oct 7;266(5182):66-71
7545954
Pathobiology. 1990;58(6):329-42
2078312
Cancer Res. 1994 May 15;54(10):2785-93
8168111
Oncogene. 2006 Apr 6;25(15):2192-202
16288209